Joseph Barney
Critical Care Medicine · Birmingham, ALNPI 1043242985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Mallinckrodt Hospital Products Inc. accounts for 80.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for critical care medicine clinicians in AL, where the typical reported total is $297.
Across 4 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$59
- Boston Scientific$14
Across 25 payments — averaging $4095.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$46K
- Mallinckrodt Enterprises LLC$30K
- Mallinckrodt Hospital Products Inc.$21K
- Bristol Myers Squibb$5K
What the payments were for
- Food & beverage$73100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 3 | $59 |
| Boston Scientific | 1 | $14 |
How this compares
$73 in reported general payments places this provider in the 25th percentile of 73 critical care medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RemicadeInfliximab | 40 | $245,786 |
| AvsolaInfliximab-Axxq | 40 | $125,148 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,019 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $15,668 |
| JardianceEmpagliflozin | 17 | $9,721 |
| Mycophenolate Mofetil | 110 | $6,882 |
| Hydroxychloroquine Sulfate | 129 | $6,721 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $5,955 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $4,621 |
| Arnuity ElliptaFluticasone Furoate | 15 | $4,475 |
| Fluticasone Propionate | 40 | $4,290 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $3,393 |
| Sirolimus | 16 | $3,136 |
| MethotrexateMethotrexate Sodium | 188 | $3,044 |
| Mycophenolic AcidMycophenolate Sodium | 14 | $3,027 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Birmingham
- James WellsBirmingham$223K
- Mark DransfieldBirmingham$160K
- George SolomonBirmingham$113K
- Tracy LuckhardtBirmingham$28K
- Keith WilleBirmingham$9K
- Victor ThannickalBirmingham$8K
- Vipul ShahBirmingham$6K
- Samuel McElweeBirmingham$5K
- Nicole SchreinerBirmingham$4K
- David LafonBirmingham$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.